Skip to main content

Table 1 (abstract O4). Characteristics of biologic initiators in the CARRA Registry

From: Proceedings of the 2018 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting

  All biologic initiators
N= 708
Non switchers n=517 Switchers n=146 Delayed switchers
n=45
Comparison of non-switchers vs switchers
P value
Age (years) median, range, IQR 10 (IQR 6, 13) 10 (6, 13) 10.5 (8, 14) 8 (4, 11) ns
Sex (F) n, % 547 (77%) 388 (75%) 119 (82%) 40 (89%) <0.05
Race: n, %      
White 582 (82%) 427 (83%) 117 (80%) 38 (84%) ns
Black 27 (4%) 19 (4%) 5 (3%) 3 (7%) ns
Asian 29 (4%) 17 (3%) 9 (6%) 3 (7%) ns
Hispanic, Latino 68 (10%) 55 (10%) 11 (8%) 2 (4%) ns
Other 13 (2%) 7 (1%) 5 (3%) 1 (2%) ns
JIA subtype: n, %      ns
 RF+ poly 90 (13%) 69 (13%) 16 (11%) 5 (11%)  
 RF- poly 376 (53%) 278 (54%) 71 (49%) 27 (60%)  
 Persistent Oligo 66 (10%) 51 (10%) 11 (8%) 4 (9%)  
Extended oligo 44 (6%) 32 (6%) 10 (7%) 2 (4%)  
 ERA 72 (10%) 49 (10%) 21 (14%) 2 (4%)  
 psoriatic 44 (6%) 27 (5%) 14 (10%) 3 (7%)  
undifferentiated 15 (2%) 10 (2%) 3 (2%) 2 (4%)  
Uveitis n, % 48 (7%) 35 (7%) 9 (6%) 4 (9%) ns
IBD n, % 18 (3%) 14 (3%) 3 (2%) 1 (2%) ns
Time from diagnosis to start biologic (days) median, range, IQR 217 (66-1126) 218 (70, 1113) 209 (54, 1211) 217 (75, 927) ns
Time from disease onset to diagnosis (days, median, IQR) 119 (48-298) 119 (47, 305) 118 (44, 278) 135 (52, 232) ns
MTX use (all) n, % 554 (78%) 394 (76%) 119 (82%) 41 (91%) <0.05
PO MTX n, % 249 (35%) 186 (36%) 45 (31%) 18 (40%) ns
SQ MTX n, % 389 (55%) 272 (53%) 87 (60%) 30 (67%) ns
sulfasalazine use n, % 36 (5%) 25 (5%) 8 (5%) 3 (7%) ns
Leflunomide use n, % 16 (2%) 12 (2%) 3 (2%) 1 (2%) ns
Calendar year of biologic start: median, IQR 2014 (2012-2015) 2014 (2013, 2015) 2014 (2012, 2015) 2012 (2010, 2014) <0.05
Medication starting: n, %      ns
TNF (all)      
 etanercept 476 (67%) 336 (65%) 103 (71%) 37(82%)  
 adalimumab 152 (21%) 118 (23%) 29 (20%) 5 (11%)  
 infliximab 36 (5%) 30 (6%) 3 (2%) 3 (7%)  
 golimumab 3 (0.4%) 2 (0.4%) 1 (0.7%) 0  
 certolizumab 3 (0.4%) 3 (0.6%) 0 0  
Non TNF (all)      
 tocilizumab 14 (2%) 12 (2%) 2 (1%) 0  
 abatacept 17 (2%) 11 (2%) 6 (4%) 0  
 rituximab 3 (0.4%) 3 (0.6%) 0 0  
 ustekinumab 0 0 0 0  
 anakinra 3 (0.4%) 1 (0.2%) 2 (1%) 0  
 canakinumab 1 (0.1%) 1 (0.2%) 0 0